RT Journal
A1 Robinson, Peter N.
A1 Köhler, Sebastian
A1 Oellrich, Anika
A1 Sanger Mouse Genetics Project
A1 Wang, Kai
A1 Mungall, Christopher J.
A1 Lewis, Suzanna E.
A1 Washington, Nicole
A1 Bauer, Sebastian
A1 Seelow, Dominik
A1 Krawitz, Peter
A1 Gilissen, Christian
A1 Haendel, Melissa
A1 Smedley, Damian
T1 Improved exome prioritization of disease genes through cross-species phenotype comparison
JF Genome Research 
JO Genome Research 
YR 2014 
FD February 01 
VO 24 
IS 2 
SP 340 
OP 348 
DO 10.1101/gr.160325.113 
UL http://genome.cshlp.org/content/24/2/340.abstract 
AB Numerous new disease-gene associations have been identified by whole-exome sequencing studies in the last few years. However, many cases remain unsolved due to the sheer number of candidate variants remaining after common filtering strategies such as removing low quality and common variants and those deemed unlikely to be pathogenic. The observation that each of our genomes contains about 100 genuine loss-of-function variants makes identification of the causative mutation problematic when using these strategies alone. We propose using the wealth of genotype to phenotype data that already exists from model organism studies to assess the potential impact of these exome variants. Here, we introduce PHenotypic Interpretation of Variants in Exomes (PHIVE), an algorithm that integrates the calculation of phenotype similarity between human diseases and genetically modified mouse models with evaluation of the variants according to allele frequency, pathogenicity, and mode of inheritance approaches in our Exomiser tool. Large-scale validation of PHIVE analysis using 100,000 exomes containing known mutations demonstrated a substantial improvement (up to 54.1-fold) over purely variant-based (frequency and pathogenicity) methods with the correct gene recalled as the top hit in up to 83% of samples, corresponding to an area under the ROC curve of >95%. We conclude that incorporation of phenotype data can play a vital role in translational bioinformatics and propose that exome sequencing projects should systematically capture clinical phenotypes to take advantage of the strategy presented here.